Denosumab treatment in patients with different courses of osteoporosis

Остеопороз и остеопатии

Elizaveta O. Mamedova¹  Anastasia A. Malygina¹  Liudmila Ya. Rozhinskaya¹  Zhanna E. Belaya¹  Alexander S. Lutsenko¹ 

[1] Endocrinology Research Centre;

关键词: osteoporosis;    denosumab;    rankl;    dxa;    case report;   

DOI  :  10.14341/osteo2017258-62

来源: DOAJ

【 摘 要 】

We present three clinical cases of successful osteoporosis treatment with denosumab in patients with different courses of osteoporosis: postmenopausal with bisphosphonates ineffectiveness, osteoporosis of mixed etiology in patient on thyroid stimulating hormone suppression and aromatase inhibitor therapy and a case of osteoporosis in a male caused by primary hyperparathyroidism. Mechanism of denosumab action is different from bisphosphonates: denosumab prevents osteoclast differentiation by binding to receptor activator of nuclear factor kappa-B ligand (RANKL) and thus suppressing bone resorption. Clinical trials showed that denosumab promotes further increase of bone mineral density after bisphosphonate treatment. Denosumab has been used in Russian Federation since 2012. Clinical effectiveness and safety profile make denosumab one of the first-line drugs for osteoporosis treatment.

【 授权许可】

Unknown